Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study

by Russell, T.W. et al
3rd September 2025 • comment

Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study

by Kwesi-Maliepaard, E.M et al
28th May 2025 • comment

Spike-specific IgG4 generated post BNT162b2 mRNA vaccination is inhibitory when directly competing with functional IgG subclasses

by Jerry C. H. Tam, et al.
9th May 2025 • comment

Phenotypic evolution of SARS-CoV-2 spike during the COVID-19 pandemic

by Wilhelm Furnon et al.
21st February 2025 • comment

Estimating Population Immunity to SARS-CoV-2 by Random Sampling from Primary and Secondary Healthcare

by Sam Scott et al.
21st February 2025 • comment

Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya

by Doreen Lugano, Bernadette Kutima, Makobu Kimani, Antipa Sigilai, John Gitonga, Angela Karani,, Donald Akech, Boniface Karia, Abdhalah K. Ziraba, Angela Maina, Arnold Lambisia, Donwilliams Omuoyo, Daisy Mugo, Ruth Lucinde, Sharon Owuor, Gloria Konyino, Joseph Newman, Dalan Bailey,, Eunice Nduati, George Githinji, Charles N. Agoti, Philip Bejon, J. Anthony G. Scott,, Ambrose Agweyu, Wangeci Kagucia, George M. Warimwe, Charles Sande, Lynette I. Ochola-Oyier, James Nyagwange
10th January 2025 • comment

Open Letter: Southeast Asia initiative to combat SARS-CoV-2 variants (SEACOVARIANTS) consortium

by Le Nguyen Truc Nhu et al.
14th August 2024 • comment

High SARS-CoV-2 incidence and asymptomatic fraction during Delta and Omicron BA.1 waves in The Gambia

by Sheikh Jarju et al.
21st May 2024 • comment

Clearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation

by Alex Sigal et al
22nd April 2024 • comment

Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant

by Alex Sigal et al
22nd April 2024 • comment

Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant

by Julia Stowe et al.

We recently reported vaccine effectiveness (VE) estimates against symptomatic disease with the Delta (B.1.617.2) variant.(1) After a full course, VE reached 88% with the Pfizer/BioNTech BNT162b2 vaccine and 67% with the AstraZeneca ChAdOx1 AZD1222 vaccine. This provided important evidence that despite modest reductions in protection, vaccines remain effective against Delta. However, the very recent emergence of the variant and the relatively low case numbers meant that it was not possible to estimate VE against severe disease.

14th June 2021 • comment